

SPRING GROUP MEETING

# Seattle

# Symptom Control & Quality of Life Committee

APRIL 3-6, 2024 | SEATTLE, WASHINGTON

# Cancer Control & Prevention Committees

## Leadership

Vice-Chair NCORP: ..... Dawn L. Hershman, MD, MS  
 Cancer Care Delivery Co-Chairs: ..... Dawn L. Hershman, MD, MS  
 ..... Scott D. Ramsey, MD, PhD  
 Cancer Survivorship Co-Chairs: ..... Halle C.F. Moore, MD  
 ..... Melinda L. Irwin, PhD, MPH  
 Palliative & End of Life Co-Chairs: ..... Robert S. Krouse, MD, FACS  
 ..... Marie Bakitas, DNSc, CRNP  
 Prevention and Epidemiology Co-Chairs: ..... Banu Arun, MD  
 ..... Marian L. Neuhouser, PhD, RD  
 Symptom Control & QOL Co-Chairs: ..... Michael J. Fisch, MD, MPH  
 ..... Norah Lynn Henry, MD, PhD  
 Executive Officers: ..... Katherine D. Crew, MD (CCD, Prevention,  
 ..... Symptom Control)  
 ..... Virginia Sun, PhD, MSN, RN (Palliative, Survivorship)  
 Senior Advisor: ..... Frank L. Meyskens, Jr., MD  
 Statisticians: ..... Katherine Guthrie, PhD  
 ..... Cathy Tangen, DrPH  
 ..... Joseph M. Unger, PhD  
 ..... Kathryn B. Arnold, MS  
 ..... Amy K. Darke, MS  
 ..... Danika Lew, MA  
 ..... Sarah Colby, MS  
 Administrative Lead SDMC: ..... Monica Yee, CCRP

## Scientific Leadership

NCORP Representative: ..... Scott Edward Delacrois, Jr., MD  
 ..... Helen Heng-Shan Moon, MD  
 Radiation Oncology: ..... Eileen P. Connolly, MD, PhD (CCD, Prevention)  
 ..... Kiri A. Cook, MD (Survivorship, Symptom Control)  
 ..... Erin F. Gillespie, MD (Symptom Control)  
 Surgery Committee: ..... Robert S. Krouse, MD, FACS  
 Translational Medicine: ..... James Rae, PhD  
 Liaisons:  
 Barlogie-Salmon Myeloma Committee: ..... Charles S. Kuzma, MD  
 Breast Committee: ..... Mariya Rozenblit, MD (Survivorship)  
 ..... Helen K. Chew, MD (Symptom Control)  
 ..... Dawn Hershman, MD, MS (CCD)  
 ..... Banu Arun, MD (Prevention)  
 ..... Philip Lammers, MD  
 Early Therapeutics & Rare Cancers: ..... Lara E. Davis, MD (Survivorship)  
 ..... Jason M. Prosek, MD  
 Gastrointestinal Committee: ..... Jason A. Zell, DO (Prevention)  
 ..... Afsaneh Barzi, MD (CCD)  
 Genitourinary Committee: ..... Clara Hwang, MD  
 ..... Sarah P. Psutka, MD

International Liaison: ..... Kathy S. Albain, MD  
 Leukemia Committee: ..... Stephanie B. Tsai, MD  
 Lung Committee: ..... Gary E. Goodman, MD  
 Lymphoma Committee: ..... Hayder Saeed, MD  
 Melanoma Committee: ..... Sancy Leachman, MD, PhD  
 ..... Thach-Giao Truong, MD (Survivorship)  
 Recruitment & Retention: ..... Allison M. Caban-Holt, PhD  
 Digital Engagement: ..... Jennifer R. Klemp, PhD (Survivorship)  
 ..... Krishna Soujanya Gunturu, MD (Survivorship)  
 ..... Mina S. Sedrak, MD (CCD)  
 ..... Katherine D. Crew, MD (Prevention)  
 ..... Michael J. Fisch, MD (Symptom Control)  
 Veterans Affairs: ..... Yeun-Hee Anna Park, MD (Symptom Control)  
 ..... Neha Patel, MD (Survivorship)  
 ..... Jacqueline Ann Gesek, BSN, RN (Nursing)

## Designates

### Oncology Research Professionals:

CRAs: ..... Amanda R. Dinsdale, MHA, CCRC  
 ..... Amy Jo Koffarnus, BS, CCRP  
 ..... Samantha Wright, MS, CCRP  
 ..... Shirley S. Sui, BS  
 Nurses: ..... Connie Szczepanek, RN, BSN  
 ..... Melyssa W. Foust, MSN, RN  
 Pharmaceutical Sciences Committee: ..... Kimberly McConnell, PharmD  
 ..... Siu-Fun Wong, PharmD  
 ..... Sun "Coco" Yang, PharmD, PhD  
 SDMC Data Coordinators: ..... Kimberly Carvalho, BA  
 ..... Sam Dzingle, BA  
 ..... Matthew Eng, PharmD  
 ..... Diane Liggett, BS, CCRP  
 ..... Roxanne Topacio, CCRP  
 ..... Monica Yee, BA, CCRP  
 Recruitment & Retention Specialist: ..... Jamie Sundstrom, BS  
 Patient Advocates: ..... Barbara Segarra-Vazquez, DHSc (CCD)  
 ..... Amy Geschwender, PhD (Symptom Control)  
 ..... Hartley "Lee" M. Jones, MBA (Survivorship)  
 ..... Cheryl L. Jernigan, CPA (Prevention)  
 ..... Valerie Fraser (Palliative)  
 Sr. Protocol Project Manager (CCD and Prevention): ..... Patricia O'Kane  
 Protocol Project Manager (Survivorship): ..... Megan Keim  
 Protocol Project Manager (Symptom Control): ..... Justine Trevino  
 Protocol Project Manager (Palliative Care): ..... Andrea Garcia  
 Clinical Trials Program Manager (Palliative Care): ..... Laura Gildner, MS  
 Clinical Trials Program Manager (CCD; Prevention;  
 Survivorship; Symptom Control): ..... Mariah Norman, MS

# Symptom Control & Quality of Life Committee

## Leadership

Co-Chairs: ..... Michael J. Fisch, MD, MPH  
 ..... Norah Lynn Henry, MD, PhD

## Time/Location

Thursday, April 4, 2024 10:15 a.m. - 12:15 p.m.  
 Room: Elwha AB (Level 5)

## Agenda

### Presentations

Integrative Oncology: Emerging Paradigms of Care Delivery and Priority Research Questions; Plenary speaker: Richard T. Lee, MD

Immunotherapy response and toxicity: the role of lifestyle factors; Plenary Speaker: Jennifer L. McQuade MD, MS, MA, LAc

### Active Studies

**S2013**, "Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study." Drs. Gunturu, Hershman, Kuderer, et al. Activated: 8/16/21.

**S2205**, "ICE COMPRESS: Randomized Trial of Limb Cryocompression Versus Continuous Compression Versus Low Cyclic Compression for the Prevention of Taxane-Induced Peripheral Neuropathy." Drs. Accordino, Pennington, Hershman, et al. Activated: 3/16/23.

**S2010**, "A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone to Improve Persistence with Endocrine Therapy in Young Women with Stage I-III Breast Cancer (ASPEN)." Drs. Henry, Hershman, and Skaar. Activated: 1/17/23.

### Other Concepts in Development

Weight management prior to radical prostatectomy to improve quality of life and obesity-driven prostate cancer biomarkers. Dr. Hamilton-Reeves

A phase III study evaluating a mindfulness tool to ameliorate treatment-related fatigue in patients with advanced renal cell carcinoma (RCC) Drs. Bergerot and Pal

Emerging from the Haze™ (Haze)- A multi-dimensional, psycho-educational, cognitive rehabilitation program to improve perceived cognitive function for cancer survivors. Dr. Myers

Acupuncture to decrease symptom burden in patients with metastatic breast cancer. Dr. Greenlee

## Closed Studies

**S1600**, "A Randomized Phase III Double-Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes (SIMMune)." Drs. Hamilton-Reeves, Holzbeierlein, Kukreja, et al. Permanently closed 10/20/23.

**S1614**, "A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors." Drs. Hwang, Lok, Gehring, et al. Permanently closed 11/15/22.

**S1714**, "A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients." Drs. Trivedi, Hershman, Brannagan, et al. Activated: 3/1/19; Permanently closed 11/15/21.

**S0702** "A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients with Bone Metastases Starting Zoledronic Acid Treatment." Dr. Van Poznak, Activated 12/15/2008. Closed 12/13/2013.

**S1200**, "Randomized Blinded Sham- and Waitlist-Controlled Trial of Acupuncture for Joint Symptoms Related to Aromatase Inhibitors in Women with Early Stage Breast Cancer." Dr. Hershman. Activated: 3/27/2012. Closed: 2/15/2017

## Committee Business

1. What other studies are we planning?
2. What is happening with our open studies?
3. What other updates should we know about?
  - Patient Advocate Update
  - Statistical Center Update

## Other SWOG Studies with Symptom Control and QOL Component

### Breast

**S1706**, "A Phase II Randomized, Double-Blinded, Placebo-Controlled Trial of Olaparib Administered Concurrently with Radiotherapy for Inflammatory Breast Cancer." Dr. Jagsi. Activated: 9/12/18.

### Cancer Care Delivery

**S1703**, "Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease

# Symptom Control & Quality of Life Committee

Monitoring (Strmddm) Versus Usual Care in Patients with Metastatic Hormone Receptor Positive Her-2 Negative Breast Cancer." Drs. Accordino, Hershman, and Ramsey. Activated: 7/16/18.

**S1912CD**, "A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)." Drs. Shankaran, Carlos, Hershman, et al. Activated: 7/26/21.

**S2108CD**, "A Cluster Randomized Trial Comparing an Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy." Drs. Reuter, Trivedi, Symington, et al. Activated: 8/22/22.

## GU

**S1802**, "Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer." Dr. Chapin. Activated: 9/17/18.

**S1806**, "Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer." Dr. Singh. Activated: 4/19/18.

## Leukemia

**S1925**, "Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study." Drs. Stephens, Hill, Pagel, et al. Activated: 12/14/20.

## Lung

**S1914**, "A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC#783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC." Drs. Daly, Simone, Kelly, et al. Activated: 3/25/20.

**S1827**, "MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)." Drs. Rusthoven, Brown, Wefel, et al. Activated: 1/10/20.

## Lymphoma

**S1826**, "A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age  $\geq$  12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma." Drs. Herrera, Friedberg. Activated: 7/19/19.

**S1918**, "A Phase II/III Randomized Study of R-miniCHOP with or without Oral Azacitidine (CC-486) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIb Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements." Drs. Brem, Smith, Henry, et al. Activated: 3/19/21.

## Myeloma

**S1803**, "Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)." Drs. Krishnan, Chhabra, and Callander. Activated: 6/27/19.

## Prevention and Epidemiology

**S0820**, "A Double-Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III – Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)." Drs. Zell, Brown, Lance, et al. Activated: 3/1/13.

**S1904**, "Cluster Randomized Controlled Trial of Patient and Provider Decision Support To Increase Chemoprevention Informed Choice Among Women with Atypical Hyperplasia or Lobular Carcinoma in Situ - Making Informed Choices on Incorporating Chemoprevention into Care (MiCHOICE)." Drs. Crew, Kukafka, Hershman, et al. Activated: 9/1/20.

## NCTN Studies

**CTSU/NRG-GI004**, "Colorectal Cancer Metastatic dMMR Immunotherapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or Without Atezolizumab or Atezolizumab Monotherapy in the First Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer." Dr. Overman. Activated: 11/7/17; Temporarily closed: 6/4/20; Reactivated: 1/29/21.

# Symptom Control & Quality of Life Committee

## Publications

The publications listed below were received by the Group Chair's Office as published (including online), accepted, or submitted since the SWOG Fall 2023 Group Meeting. Conference abstracts are not included.

Because of journal embargo policies, journal names are omitted for submitted or accepted manuscripts.

### Published/Accepted Manuscripts

S0221 Vitamin D insufficiency as a risk factor for paclitaxel-induced peripheral neuropathy in White and Black patients in SWOG S0221. Chen C, Zirpoli G, McCann S, Barlow W, Budd GT, Puzstai L, Henry NL, Godwin A, Thompson A, Ambrosone C, Stringer K, Hertz D. Journal of the National Comprehensive Cancer Network Nov;21(11):1172-1180.e3, 2023. <https://pubmed.ncbi.nlm.nih.gov/37935109/> [see also Breast and Pharmaceutical Sciences Committees]

### Submitted Manuscripts

S1316 Intake and Nutritional Adequacy in Cancer Patients Diagnosed with Malignant Bowel Obstruction: A secondary analysis of a randomized trial. CA Thomson CA, KB Arnold KB, Anderson G, Sun V, Secord A, Yung A, Al-Kaspooles M, Nfonsam V, Grant M, Deutsch G, . Deneve J, Krouse R. Submitted 2024.

# Symptom Control & Quality of Life Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

	S1600	S1614	S2010	S2013	S2205	A221805	A222004	EAQ202	NRGCC010
Ascension Providence Hospitals - Southfield	-	-	-	29	-	-	-	-	-
Audie L Murphy VA Hospital	-	-	-	11	-	-	-	-	-
Banner MD Anderson Cancer Center	-	-	-	-	-	1	-	-	-
Banner University Medical Center - Tucson	-	-	-	4	-	-	-	-	-
Bay Area Tumor Institute NCORP	-	-	-	-	3	-	-	-	-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	5	-	-	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-	2	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	1	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-	-	97	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	1	14	-	-	-	-	-
City of Hope Comprehensive Cancer Center	6	-	-	-	-	-	-	-	-
Columbia University Minority Underserved NCORP	-	-	2	24	8	-	1	-	-
Columbus NCI Community Oncology Research Program	-	-	-	29	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	7	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-	-	-	1	-	-	-
Fred Hutchinson Cancer Research Center LAPS	13	-	-	-	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	-	-	-	14	-	-	-	-	-
Georgia NCI Community Oncology Research Program	-	-	4	64	-	-	-	-	-
Grupo Oncologico Cooperativo de Investigacion	-	-	-	4	-	-	-	-	-
Gulf South Minority Underserved NCORP	1	-	2	22	-	-	-	-	5
Hawaii Minority Underserved NCORP	-	-	3	1	-	-	-	-	-
Heartland Cancer Research NCORP	-	-	15	210	-	-	-	-	-
Henry Ford Hospital	8	-	-	-	-	-	-	-	-
Instituto Nacional de Enfermedades Neoplasicas	-	-	13	-	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	2	9	57	-	-	-	-	-
Lahey Hospital and Medical Center	-	-	5	52	-	-	-	-	-
Massachusetts Veterans Epidemiology Research and Information Center	-	-	-	47	-	-	-	-	-
Mercy Medical Center - Des Moines	-	-	-	9	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	2	-	-	-	-	-	-

# Symptom Control & Quality of Life Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

	S1600	S1614	S2010	S2013	S2205	A221805	A222004	EAQ202	NRGCC010
Montana Cancer Consortium NCORP	-	-	-	4	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-	-	-	-	-	39	-
Nevada Cancer Research Foundation NCORP	-	-	-	-	-	-	-	4	-
New Mexico Minority Underserved NCORP	-	-	7	-	1	-	-	-	-
Northwestern University LAPS	-	-	4	-	-	-	-	-	-
Oregon Health and Science University	-	-	-	12	-	-	-	-	-
Pacific Cancer Research Consortium NCORP	-	-	2	2	-	-	-	-	-
SCL Health Saint Joseph Hospital	-	-	-	1	-	-	-	-	-
STCC at DHR Health Institute for Research and Development	-	-	8	40	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	1	120	14	-	-	-	-
The Don and Sybil Harrington Cancer Center	-	-	2	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	-	5	9	-	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	-	6	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	78	-	-	10	-	-	-	-	-
Universidad de la Republica - Facultad de Medicina	-	-	-	13	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	4	21	-	-	-	-	-
University of Colorado Cancer Center LAPS	14	-	-	30	-	2	-	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	51	-	6	69	8	2	-	-	-
University of Michigan Comprehensive Cancer Center LAPS	-	-	13	-	-	-	-	-	-
University of Mississippi Medical Center	-	-	1	-	-	-	-	-	-
University of Rochester LAPS	16	-	-	-	-	-	-	-	-
University of Texas Health Science Center at San Antonio	-	-	7	45	-	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	1	-	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	1	3	-	-	2	-	-
Wisconsin NCI Community Oncology Research Program	-	-	2	24	-	-	-	-	-
ALLIANCE	5	-	9	280	15	-	-	-	-
ECOG-ACRIN	4	-	8	90	2	-	-	-	-
NRG	2	1	19	194	7	-	-	-	-
<b>Total</b>	<b>203</b>	<b>4</b>	<b>162</b>	<b>1,662</b>	<b>58</b>	<b>8</b>	<b>3</b>	<b>43</b>	<b>5</b>

